Clinical Trial Update: A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN) [Phase 1, Phase 2]

View source ↗

Summary

This is a dose-escalating Phase 1/2 trial evaluating obinutuzumab in CD20+ malignant diseases (lymphoma). The study has completed and results were posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Obinutuzumab (Gazyva) (obinutuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-09-22